前列腺癌患者睾酮替代治疗的安全性研究进展  

Research progress on the safety of testosterone replacement therapy in patients with prostate cancer

作　　者：汪奇波 朱绍兴 WANG Qi-bo;ZHU Shao-xing(Department of Urology,Cancer Hospital of the University of Chinese Academy of Sciences,Zhejiang Province,Hangzhou310022,China)

机构地区：[1]中国科学院大学附属肿瘤医院泌尿外科,浙江杭州310022

出　　处：《中国当代医药》2020年第8期16-18,共3页China Modern Medicine

基　　金：浙江省自然科学基金资助项目(LY16H160034)。

摘　　要：男性性腺功能减退症是由于雄激素缺乏引起的一种临床综合征,睾酮替代治疗(TRT)是其首选治疗方法.但对于既往有前列腺癌病史的患者,TRT的应用一直存在争议.近年来,文献报道了不同阶段前列腺癌患者接受TRT的安全性研究,包括癌前病变期,主动监测、根治性治疗后及进展期前列腺癌.本文回顾这些文献并对TRT在前列腺癌患者中应用的安全性研究进展进行综述.Hypogonadism in men is a clinical syndrome caused by androgen deficiency,for whom testosterone replacement therapy(TRT)is the preferred treatment.However,the use of TRT has been controversial in patients with a previous history of prostate cancer.In recent years,studies on the safety of TRT in patients with prostate cancer at different stages have been reported,including pre-cancerous stage,active surveillance,post-radical treatment and advanced prostate cancer.This article reviews the literatures and the progress in the application safety of TRT in patients with prostate cancer.

关 键 词：前列腺癌 性腺功能减退症 睾酮 替代治疗 

分 类 号：R458.7[医药卫生—治疗学]